Valuation: Replimune Group, Inc.

Market Cap 1.47B 1.27B 1.19B 1.08B 2.04B 141B 2.07B 13.99B 5.48B 70.34B 5.51B 5.39B 234B P/E 2027 *
-5.45x
P/E 2028 * -7.56x
Enterprise Value 1.39B 1.2B 1.13B 1.03B 1.93B 133B 1.96B 13.26B 5.2B 66.65B 5.22B 5.11B 222B EV / Sales 2027 *
32.6x
EV / Sales 2028 * 7.65x
Free-Float
96.38%
Yield 2027 *
-
Yield 2028 * -
1 day+6.49%
1 week+14.14%
Current month+39.11%
1 month+52.30%
3 months+210.98%
6 months+93.78%
Current year+60.29%
1 week 14.05
Extreme 14.05
15.7
1 month 4.76
Extreme 4.7648
15.7
Current year 1.5
Extreme 1.5
15.7
1 year 1.5
Extreme 1.5
15.7
3 years 1.5
Extreme 1.5
21.32
5 years 1.5
Extreme 1.5
35.93
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Chairman 54 01/04/2024
Director/Board Member 66 01/07/2017
Chairman 65 01/04/2020
Date Insider Type Main position Quantity % Market Cap.
11/08/26
Baker Bros. Advisors LP
BuyCompany 2,736,340 3.5056%
10/08/26 Sell

Controller/Auditor

-7,632 0.0098%
10/08/26 Sell

Chief Financial Officer

-11,448 0.0147%
Change 5-day change 1-year change 3-year change Capi.($)
+6.49%+14.14%+192.31%-19.86% 1.38B
-0.11%-1.67%+1.80%+19.90% 48.84B
+1.89%+5.08%+492.59%+629.24% 45.44B
+1.83%+2.75%+15.61%+91.22% 41.22B
-0.50%-1.56%+24.67%+12.17% 39.71B
-2.74%-7.13%+18.72%+49.04% 32.6B
-1.14%-2.51%+27.52%+136.42% 16.67B
+0.59%-2.25% - - 16.25B
-0.49%-0.34%+3.45%+29.14% 14.08B
-2.60%-1.00%+77.85%+40.37% 13.68B
Average +0.32%+0.62%+94.95%+109.74% 26.99B
Weighted average by Cap. +0.01%-0.33%+104.65%+152.26%

Financials

2027 *2028 *
Net sales 42.73M 36.9M 34.72M 31.56M 59.35M 4.09B 60.22M 407M 160M 2.05B 160M 157M 6.82B 182M 157M 148M 134M 253M 17.42B 256M 1.73B 679M 8.71B 683M 668M 29.02B
Net income -297M -257M -241M -219M -413M -28.47B -419M -2.83B -1.11B -14.24B -1.12B -1.09B -47.42B -202M -175M -165M -150M -281M -19.4B -285M -1.93B -756M -9.7B -760M -744M -32.31B
Net Debt -77M -66.5M -62.57M -56.87M -107M -7.38B -109M -734M -288M -3.69B -289M -283M -12.29B -77M -66.5M -62.57M -56.87M -107M -7.38B -109M -734M -288M -3.69B -289M -283M -12.29B
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
18/08/26 $15.58 +6.49% 2,244,873
17/08/26 $14.63 -2.27% 3,735,001
14/08/26 $14.97 -1.45% 2,398,900
13/08/26 $15.19 -0.33% 3,220,712
12/08/26 $15.24 +11.65% 8,272,476
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.58USD
Average target price
19.33USD
Spread / Average Target
+24.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock